FDA Generics Office Hopes To Begin Increasing Staff By Year-End
This article was originally published in The Pink Sheet Daily
To aid in ANDA assignments, OGD is developing a program to prioritize submissions as the agency addresses a 3,000-application backlog, OGD Deputy Director Robert West says during regulatory affairs specialists’ gathering in Seattle.
You may also be interested in...
A rare government report criticizes practices of China’s generics industry and SFDA, officially highlighting well-recognized problems – from a lengthy registration process to a lack of pricing and bidding incentives – which need urgent attention.
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.